Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 24 (6), 1215-24

Sample Size Calculations for the Development of Biosimilar Products

Affiliations

Sample Size Calculations for the Development of Biosimilar Products

Seung-Ho Kang et al. J Biopharm Stat.

Abstract

The most widely used design for a Phase III comparative study for demonstrating the biosimilarity between a biosimilar product and a renovator biological product is the equivalence trial, whose aim is to show that the difference between two population means of a primary endpoint is less than a prespecified equivalence margin. A well-known sample size formula for the equivalence trial is given by [Formula: see text] Since this formula is obtained based on the approximate power rather than the exact power, we investigate in this article the accuracy of the sample size formula. We conclude that the sample size formula is very conservative. Specifically, we show that the exact power based on the sample size calculated from the formula to have power [Formula: see text] is actually [Formula: see text] under some conditions. Therefore, the use of the sample size formula may cause a huge extra cost to biotechnology companies. We propose that the sample size should be calculated based on the exact power precisely and numerically. The R code to calculate the sample size numerically is provided in this article.

Keywords: Equivalence trial; Follow-on biologics; Margin; Power; Sample size formula.

Similar articles

See all similar articles

Publication types

MeSH terms

Substances

LinkOut - more resources

Feedback